Events - 08 Mar 09:00FDA public meeting on vitiligo

Event

Silver Spring, MD, USA

UPDATE: FDA is announcing a new date for the meeting. The public meeting will be held on March 8, 2021 from 10 a.m. to 2:30 p.m. EST, in a virtual (online only) format. Please save this date and time if you are interested in attending this public meeting.

US Food and Drug Administration (FDA) is conducting its first public meeting on Patient-Focused Drug Development for Vitiligo. The meeting is intended to allow FDA to obtain patient perspectives on the impact of vitiligo, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment. 

Additional information about the meeting can be found on the meeting webpage. The webpage will be updated as meeting materials are developed, and registration will be available closer to the meeting date.

Please email the PFDD Staff at patientfocused@fda.hhs.gov if you have any questions.

FAQOther Questions

  • Which skin conditions can be mistaken for vitiligo?

    Vitiligo is a common skin condition with characteristic milky white patches of irregular shape. However, several other skin conditions exhibit similar symptoms that can lead to ...

  • Can chemicals cause vitiligo?

    It’s important to remember there are multiple factors involved in vitiligo onset, including genetic predisposition, living and working environments, and exposure to certain chem...

  • What's better: laser or phototherapy?

    In a recent study researchers assessed effect and safety of different laser and phototherapy treatments, such as excimer laser/light, narrowband UVB, UVA and PUVA. No significa...